Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study

Abstract

Our objective was to determine the effect of 1 year low-dose cyclosporine A (CSA) treatment on disease activity and renal involvement in systemic lupus erythematosus (SLE). Patients included in the pilot study had an active form of the disease as defined by the SLE Disease Activity Index (SLEDAI). Main organ involvement was represented by lupus nephritis classified in repeated renal biopsies. Eleven patients with SLE were enrolled in the study. In eight of them, previous therapy with cyclophosphamide or azathioprine had to be interrupted due to serious adverse reaction or low efficacy. Nine patients experienced clinical nephrotic syndrome, and two the nephritic syndrome. After 12 months of CSA treatment, the mean SLEDAI score had decreased significantly from 26.18 to 4.00 (P < 0.01). Similarly, the titre of antinuclear and anti-dsDNA antibodies had dropped significantly (P < 0.01). Proteinuria decreased rapidly from 9.10 to 1.70 g/24 h (P < 0.001). According to the WHO classification of renal biopsies, three patients had their class altered from IV to III in response to CSA treatment and five patients had changed the status from the high severity grade to the mild. The adverse reactions included hypertension (45%), gingival hyperplasia (18%) and hirsutism (9%). No significant increase in serum creatinine or any CSA related toxic changes were found in renal biopsies. The favourable response observed in patients with active SLE and with major renal involvement strongly suggests that low-dose CSA is a potent drug as much for the reduction of the disease activity as for lupus nephropathy treatment.

Keywords

lupus nephropathy treatment cyclosporine A

References

Boumpas DT et al. SLE: emerging concepts. Part 1 . Ann Internal Med 1995; 122: 940–950 , Part 2. 123: 42–53.

Steinberg AD , Gourley M. Cyclophosphamide in lupus nephritis ; J Rheumatol 1995; 22: 1812–1815 .

Klippel JH. Curing lupus views from the foothills . Ann Rheum Dis Leaders. 1994; 53: 785–786 .

Kahan BD. Cyclosporine . N Engl J Med 1989; 321: 1725–1734 .

Cruse JM , Lewis RE Jr. Cyclosporin therapy of autoimmune disease. In Therapy of Autoimmune Disease. JM Cruse, RE Lewis Jr, Karger, Basel : 1989.

Radhakrishnan J , Valeri K , Kunis C , Appel GB. Use of cyclosporin in lupus nephritis.(ed.). Tejani A Karger : 1995, Basel. In Cyclosporin in the Therapy of Renal Disease. 59–72.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

Bombardieri C et al. and the Committee on Prognostic Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients .; Arthritis Rheum 1992; 35: 630–640 .

Churg J , Bernstein J , Glassock RJ. Renal Disease. Classification and Atlas of Glomerular Diseases; (2nd edn). New York, Tokyo, Igaku-Shoin : 1995.

10.

Isenberg DA , Snaith ML , Morrow NJW . Effects of cyclosporin in severe systemic lupus erythematosus . J Pediatr 1987; 111: 1063–1068 .

11.

Feutren G et al. Effects of cyclosporin in severe systemic lupus erythematosus . J Pediatr 1987; 111: 1063–1068 .

12.

Miescher PA , Miescher A. Combined cyclosporin-steroid treatment of systemic lupus erythematosus. Cyclosporin in Autoimmune Disease (ed.) R. Schneider . Springer Berlin , 1985.

13.

Favre H et al. Cyclosporine in the treatment of lupus nephritis . Am J Nephrol 1989; 9 (Suppl.): 57–60 .

14.

Collaboration study group of Sandimmun Nephrotic syndrome safety and tolerability of Cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome . Clin Nephrol 1991; 35 (Suppl. 1): 48–60 .

15.

Cattran DC. Current status of cyclosporin A in the treatment of membranous IgA and membranoproliferative glomerulonephritis . Clin Nephrol 1991; 35 (Suppl. 1): 43–47 .

16.

Guasch A et al. Short-term responsiveness of membranous glomerulopathy to Cyclosporine . Ann J Kidney Dis 1992; 20: 472–481 .

17.

Radhakrishnan J , Kunis CL , D'Agati V , Appel GB. Cyclosporine treatment of lupus membranous nephropathy . Clin Nephrol 1994; 42: 147–154 .

18.

Tokuda M et al. Effect of low-dose cyclosporine A on SLE disease activity . Arthritis Rheum 1994; 37: 551–558 .

19.

Bloemena E et al. Prednisolone and cyclosporine A exert differential inhibitory effects on T cell proliferation in vitro . Clin Immunol Immunopathol 1988; 48: 380–391 .

20.

Fraenkel L et al. Response to the treatment as a predictor of long term outcome in patients with lupus nephritis . J Rheumatol 1994; 21: 2052–2057 .

21.

Caccavo D et al. Long-term treatment of systemic lupus erythematosus with cyclosporine A . Arthritis Rheum 1997; 40: 27–35 .